GlassScriptPhysician profile
Kenneth D Dabolt
NPI 1881189116
$6,842.69
in general payments reported to CMS, 2019-2025
34 companies · $1,485 in 2025
The $1,485 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $313 · 2022: $1,229 · 2023: $2,087 · 2024: $1,729 · 2025: $1,485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,301.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,125.15 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $843.77 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $650.73 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $470.76 | 2022-2025 | |
| Glaxosmithkline, LLC. | $420.37 | 2022-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Gilead Sciences, INC. | $324.51 | 2022-2023 | Epclusa |
| Amgen INC. | $199.72 | 2023-2025 | Otezla, Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $198.67 | 2022-2025 | Xifaxan |
| Pfizer INC. | $154.60 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $142.02 | 2022-2024 | Gardasil 9, Vaxneuvance, Vaxelis |
| Bayer Healthcare Pharmaceuticals INC. | $134.10 | 2022-2024 | |
| Exact Sciences Corporation | $120.83 | 2023-2025 | Cologuard Collection Kit |
| Edwards Lifesciences Corporation | $115.60 | 2022-2025 | Sapien 3 Ultra Resilia |
| Abbott Laboratories | $100.00 | 2021-2025 | Freestyle Libre 3 |
| Axsome Therapeutics, INC. | $87.96 | 2025 | Auvelity |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $73.53 | 2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $68.81 | 2022-2024 | Rexulti |
| Aimmune Therapeutics, INC. | $67.30 | 2024 | |
| Astellas Pharma US INC | $66.45 | 2024-2025 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $58.70 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $56.37 | 2025 | Caplyta |
| Alk-Abello, INC | $53.72 | 2023 | Grastek, Ragwitek, Odactra |
| Dexcom, INC. | $48.32 | 2022-2024 | Dexcom G6 Transmitter |
| Lundbeck LLC | $43.32 | 2023-2024 | Rexulti |
| Shield Therapeutics INC | $38.74 | 2023-2024 | Accrufer |
| E.R. Squibb & Sons, L.L.C. | $29.69 | 2022-2025 | Camzyos |
| Alnylam Pharmaceuticals INC. | $24.40 | 2023 | Onpattro |
| Inspire Medical Systems, INC. | $22.68 | 2025 | Inspire |
| Collegium Pharmaceutical, INC. | $19.51 | 2023 | Xtampza |
| Kowa Pharmaceuticals America, INC. | $19.50 | 2022 | |
| Insulet Corporation | $18.66 | 2024 | Omnipod |
| Sanofi-Aventis U.S. LLC | $15.05 | 2023 | |
| Paratek Pharmaceuticals, INC. | $14.61 | 2025 | Nuzyra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Dabolt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.